DOCSLIB.ORG

IIIIIIIIIIIIIIIIIIIIIIIIIIIUS010071103B2 (12 ) United States Patent ( 10) Patent No

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
IIIIIIIIIIIIIIIIIIIIIIIIIIIUS010071103B2 (12 ) United States Patent ( 10) Patent No IIIIIIIIIIIIIIIIIIIIIIIIIIIUS010071103B2 (12 ) United States Patent ( 10 ) Patent No. : US 10 ,071 , 103 B2 Sengupta et al. (45 ) Date of Patent: Sep . 11 , 2018 ( 54 ) TREATMENTS FOR RESISTANT ACNE ( 58 ) Field of Classification Search CPC .. A61K 31 /55 ; A61K 9 /0014 ; A61K 31/ 192 ; (71 ) Applicant: VYOME BIOSCIENCES PVT. LTD . , A61K 31 /4709 ; A61K 45 /06 ; A61K New Delhi ( IN ) 47 / 02 , A61K 47 / 08 ; A61K 47 / 10 ; A61K 47 / 183 ; A61K 47 /32 , A61K 47 / 36 ; A61K (72 ) Inventors : Shiladitya Sengupta , Delhi ( IN ) ; 47 /38 Suresh Rameshlal Chawrai, Pune USPC . .. .. .. 514 /210 . 16 ( IN ) ; Shamik Ghosh , Delhi ( IN ) ; See application file for complete search history . Sumana Ghosh , Delhi ( IN ) ; Nilu Jain , New Delhi ( IN ) ; Suresh Sadhasivam , ( 56 ) References Cited Salem ( IN ) ; Richard Buchta , Melbourne (AU ) ; Anamika U . S . PATENT DOCUMENTS Bhattacharyya , Delhi ( IN ) 4 , 668 ,664 A 5 / 1987 Rougier et al. 5 ,607 , 980 A 3 / 1997 McAtee et al . ( 73 ) Assignee: VYOME BIOSCIENNCES PVT. 6 , 255, 279 B1 7 / 2001 Christophers et al. LTD ., New Delhi ( IN ) 2005 / 0209157 Al 9 /2005 Owen 2005 /0245545 Al 11/ 2005 Kase et al . Subject to any disclaimer, the term of this 2005 /0282755 Al 12 /2005 Hart et al . ( * ) Notice : 2006 / 0008538 A1 1 / 2006 Wu et al . patent is extended or adjusted under 35 2007/ 0134729 AL 6 / 2007 Christensen et al. U . S . C . 154 ( b ) by 0 days. 2007 / 0197501 A1 8 / 2007 Schulz et al . 2011/ 0144329 A1 * 6 / 2011 Shawer . .. .. CO7D 223 / 12 ( 21 ) Appl. No .: 15 / 115 , 143 540 /605 2016 / 0058775 A1 * 3 / 2016 Prasad .. .. .. A61K 8 /342 ( 22 ) PCT Filed : Jan . 29 , 2015 424 / 401 ( 86 ) PCT No. : PCT/ IN2015 / 000057 FOREIGN PATENT DOCUMENTS $ 371 ( c ) ( 1 ), CN 103524492 A 1 / 2014 ( 2 ) Date : Jul. 28 , 2016 EP 0251330 A2 1 / 1998 JP 2009196934 A 9 / 2009 WO 2006 / 100495 A1 9 / 2006 (87 ) PCT Pub. No. : W02015 /114666 WO 2007 /070518 A2 6 / 2007 PCT Pub . Date : Aug. 6 , 2015 WO 2008 /035078 A1 3 / 2008 WO 2012 / 177770 A112 / 2012 wo 2012 / 177986 A2 12 / 2012 (65 ) Prior Publication Data WO 2014 / 167554 A2 10 / 2014 US 2016 /0346294 A1 Dec. 1 , 2016 WO 2014 / 195872 A112 / 2014 (30 ) Foreign Application Priority Data OTHER PUBLICATIONS Jan . 29 , 2014 ( IN ) . .. .. .. .. .. .. .. .. .. .. 269 /DEL /2014 Betriu et al . , “ Erythromycin and Clindamycin Resistance and Nov . 10 , 2014 ( IN ) .. .. .. .. 3247 /DEL / 2014 Telithromycin Susceptibility in Streptococcus agalactiae” , Antimi crobial Agents and Chemotherapy 47 ( 3 ) : 1112 - 1114 (2003 ) . (51 ) Int. CI. Bryskier et al. , “ Dual B - lactam - fluoroquinolone compounds: a novel A61K 31 /55 ( 2006 .01 ) approach to antibacterial treatment” , Expert Opinion on Investiga A61K 31/ 192 ( 2006 .01 ) tional Drugs 6 ( 10 ) : 1479 - 1499 ( 1997 ) . Cambau et al ., “ Target specificity of the new fluoroquinolone A61K 45 / 06 ( 2006 .01 ) besifloxacin in Streptococcus pneumoniae , Staphylococcus aureus A61K 47 / 02 ( 2006 . 01 ) and Escherichia coli” , Journal of Antimicrobial Chemotherapy A61K 47 / 08 ( 2006 .01 ) 63 : 443 -450 (2009 ) . A61K 47 / 10 ( 2017 .01 ) De Lucca et al. , “ Antifungal peptides : Origin , activity , and thera C07D 513 /04 ( 2006 .01 ) peutic potential" , Revista Iberoamericana de Micologia 17 : 116 - 120 A61K 31 / 4709 ( 2006 .01 ) ( 2000 ) . A61K 9 / 00 ( 2006 . 01 ) A61K 47 / 18 ( 2017 .01 ) (Continued ) A61K 4732 ( 2006 . 01 ) Primary Examiner — Yevgeny Valenrod A61K 47 / 36 ( 2006 .01 ) ( 74 ) Attorney, Agent, or Firm — Nixon Peabody LLP ; A61K 47 /38 ( 2006 .01 ) David S . Resnick ; Ravinderjit Braich (52 ) U . S . CI. CPC . .. .. .. .. A61K 31/ 55 ( 2013 .01 ) ; A61K 9 / 0014 ( 2013 . 01 ) ; A61K 31 / 192 (2013 . 01 ) ; A61K (57 ) ABSTRACT 31 /4709 (2013 .01 ) ; A61K 45 /06 (2013 .01 ) ; The present disclosure relates generally to novel molecules , A61K 47 / 02 ( 2013 .01 ) ; A61K 47 /08 ( 2013 .01 ) ; compositions, and formulations for treatment of bacterial A61K 47 / 10 ( 2013. 01 ) ; A61K 47 / 183 infections in general and more specifically to bacterial ( 2013 .01 ) ; A61K 47 /32 ( 2013 .01 ) ; A61K 47 / 36 infections with antibiotic resistant pathogens. ( 2013 .01 ) ; A61K 47/ 38 ( 2013 .01 ) ; C07D 513 /04 ( 2013 .01 ) 16 Claims, 14 Drawing Sheets US 10 ,071 , 103 B2 Page 2 References Cited loproteinases in keratinocytes in response to Propionibacterium ( 56 ) acnes" , Archives of Dermatological Research 302 :745 - 756 ( 2010 ) . Liu et al. , “ Cutting Edge : All - trans Retinoic Acid Down -Regulates OTHER PUBLICATIONS TLR2 Expression and Function ” , The Journal of Immunology 174 :2467 - 2470 (2005 ) . Elitropi et al ., “ New Cephalosporins and 7a -Methoxy Cephalosporins Mouser et al ., “ Propionibacterium acnes- Reactive T Helper - 1 Cells in the Skin of Patients with Acne Vulgaris ” , The Journal of Chemistry and Biological Activities ” , The Journal of Antibiotics Investigative Dermatology 121 ( 5 ) : 1226 - 1228 (2003 ) . 32 ( 9 ) : 900 - 908 ( 1979 ) . Nagy et al ., “ Propionibacterium acnes and lipopolysaccharide induce Epand et al. , “ Diversity of antimicrobial peptides and their mecha the expression of antimicrobial peptides and proinflammatory cytokines/ nisms of action ” , Biochimica et Biophysica Acta 1462 : 11 -28 ( 1999 ) . chemokines in human sebocytes ” , Microbes and Infection 8 : 2195 Haas et al. , “ Besifloxacin , a Novel Fluoroquinolone, Has Broad 2205 ( 2006 ) . Spectrum In Vitro Activity against Aerobic and Anaerobic Bacte Regoes et al . , “ Pharmacodynamic Functions : a Multiparameter ria ” , Antimicrobial Agents and Chemotherapy 53 ( 8 ) :3552 - 3560 Approach to the Design of Antibiotic Treatment Regimens ” , Anti ( 2009 ) . microbial Agents and Chemotherapy 48 ( 10 ) : 3670 - 3676 ( 2004 ) . Jeremy et al. , “ Inflammatory Events Are Involved in Acne Lesion Schlunzen et al . , " Structural basis for the interaction of antibiotics Initiation ” , Journal of Investigative Dermatology 121 ( 1 ) :20 - 27 (2003 ) . with the peptidyl transferase centre in eubacteria ” , Nature 413 :814 Kabara et al. , “ Fatty Acids and Derivatives as Antimicrobial Agents ” , 821 (2001 ) . Antimicrobial Agents and Chemotherapy 2 ( 1 ) :23 - 28 ( 1972 ) . Taglietti et al . , " Novel Topical Drug Delivery Systems and Their Kato et al ., “ Comparison of In Vitro Activities of DU -6859a and Potential Use in Acne Vulgaris ” , Skin Therapy Letter 1 - 5 (2008 ) . Other Fluoroquinolones Against Japanese Isolates of Anaerobic Thiboutot et al. , “ IL - 17 : A Key Player in the P . acnes Inflammatory Bacteria ” , Clinical Infectious Diseases 23 ( Suppl 1 ) : S31 - S35 ( 1996 ) . Cascade ? " , Journal of Investigative Dermatology 134 : 307 -310 ( 2014 ) . Keren et al ., " Specialized Persister Cells and the Mechanism of Toyoda et al ., “ An Overview of Topical Antibiotics for Acne Multidrug Tolerance in Escherichia coli” , Journal of Bacteriology Treatment " , Dermatology 196 ( 1 ) : 130 -134 ( 1998 ) . 186 ( 24 ) :8172 - 8180 ( 2004 ) . Zasloff M . , “ Antimicrobial peptides of multicellular organisms” , Kim et al. , " Activation of Toll - Like Receptor 2 in Acne Triggers Nature 415 : 389 -395 ( 2002 ) . Inflammatory Cytokine Responses ” , The Journal of Immunology Miller et al. , “ SOS Response Induction by B - Lactams and Bacterial 169 : 1535 - 1541 ( 2002 ) . Defense Against Antibiotic Lethality ” , Science 305 : 1629 - 1631 ( 2004 ) . Lau et al. , “ Scope and Limitations of The Co - Drug Approach to Ye et al . , " Synthesis and antibacterial activity of pyridonecarboxylic Topical Drug Delivery ” , Current Pharmaceutical Design 14 ( 8 ) :794 acid derivatives containing 2 -methyl - 5 - nitroimidazol ” , Acta 802 ( 2008 ) . Pharmaceutica Sinica 38 ( 4 ) : 260 - 263 (2003 ) . Lee et al. , “ Protease - activated receptor - 2 mediates the expression of inflammatory cytokines , antimicrobial peptides , and matrix metal * cited by examiner U . S . Patent Sep . 11, 2018 Sheet 1 of 14 US 10 ,071 , 103 B2 + Cephalothin + Nadifloxacin * Roxythromycin %viablecells - Besifloxacin * Prulifloxacin + Clindamycin + Cefoxitin # Ulifloxacin FIG . IA 150 + Cephalothin * Nadifloxacin 100k * Roxithromycin - Besifloxacin %viablecells + Ulifloxacin Prulifloxacin + Clindamycin Leo + Cefoxitin FIG . IB U . S . Patent Sep . 11, 2018 Sheet 2 of 14 US 10, 071 , 103 B2 DARTmolecules Dose response Curve Against P . acnes MTCC 1951 Ourwww sabansa WMSpH %cellsviability I 1116 115 öppna 0. 00 0. 05 0 .100 .150 .200 .250 . 30 MA Antibiotic Concentration (ugimi ) . FIG . IC DARTmolecules Dose Response Curve against P . acnes CCARM 9010 113 wwwwwwwwwwwwwwwwwwwwwwwwwwwwww trement alertow %Cellsviability 116 } 0. 00 0. 05 0. 10 0 .16 0. 20 0. 25 0 .30 . Antibiotic Concentration (ug / ml ) FIG . ID U . S . Patent Sep . 11, 2018 Sheet 3 of 14 US 10 ,071 , 103 B2 Lanes 3 - 7 Lane1 Comp. 91 conc. (um ) Lane8 IA 0 . 25come 0 .50 1one .00 come 2 . 50 come5 .00 .. , Controls Lane 1 - Relaxed DNA (Negative Control) Lane 2 - DNA + Gyrase (Positive Control) Lane 3 - 7 Comp. 91 with increasing conc . Lane 8 - Supercoiled DNA marker D ALS. TO P WUNSTAR - DL + Ito + CompoundGyrase 91 0 .25 0 . 50 1 .00 2 . 50 5 .00 Compound Conc . (um ) FIGS. 2A and 2B U . S . Patent Sep . 11, 2018 Sheet 4 of 14 US 10 ,071 , 103 B2 Vun Compound 113 AWW Compound 94 3 Compound 115 og B Compound 90 werth Um Compound 116 w HP Compound 91 Percentageofsupercoiling % Ô ? HUMIHITTITUTITI 0.211111111111 III. o ?????????????? 1uM Compound 2 . 5 uM Compound FIG . 3A AW Nadifloxacin E Compound 91 Percentageofsupercoiling Estadoe . o 1?M 2 . 5 PM FIG . 3B U . S
Load more

Recommended publications
  • WO 2015/179249 Al 26 November 2015 (26.11.2015) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2015/179249 Al 26 November 2015 (26.11.2015) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C12N 15/11 (2006.01) A61K 38/08 (2006.01) kind of national protection available): AE, AG, AL, AM, C12N 15/00 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, (21) Number: International Application DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US2015/031213 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (22) International Filing Date: KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, 15 May 2015 (15.05.2015) MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, (25) Filing Language: English SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (26) Publication Language: English TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 62/000,43 1 19 May 2014 (19.05.2014) US kind of regional protection available): ARIPO (BW, GH, 62/129,746 6 March 2015 (06.03.2015) US GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (72) Inventors; and TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, (71) Applicants : GELLER, Bruce, L.
    [Show full text]
  • Oxazolidinones for TB
    Oxazolidinones for TB: Current Status and Future Prospects 12th International Workshop on Clinical Pharmacology of Tuberculosis Drugs London, UK 10 September 2019 Lawrence Geiter, PhD Disclosures • Currently contract consultant with LegoChem Biosciences, Inc., Daejeon, Korea (LCB01-0371/delpazolid) • Previously employed with Otsuka Pharmaceutical Development and Commercialization, Inc. (delamanid, OPC-167832, LAM assay) What are Oxazolidinones • A family of antimicrobials mostly targeting an early step in protein synthesis • Cycloserine technically oxazolidinone but 2-oxazolidinone different MOA and chemical properties • New generation oxazolidinones bind to both 50S subunit and 30S subunit • Linezolid (Zyvox) and Tedizolid (Sivestro) approved for drug resistant skin infections and community acquired pneumonia Cycloserine • Activity against TB demonstrated in non- clinical and clinical studies • Mitochondrial toxicity >21 days limits use in TB treatment Linezolid Developing Oxazolidinones for TB Compound Generic Brand Sponsor Development Status TB Code- Activity/Trials PNU-100766 Linezolid Zyvox Pfizer Multiple regimen Yes/Yes TR-201 Tedizolid Sivextro Merck Pre-clinical efficacy Yes/No PNU-100480 Sutezolid Pfizer Multiple regimen studies Sequella Yes/Yes (PanACEA) TB Alliance LCB01-0371 Delpazolid LegoChem Bio EBA trial recruitment completed Yes/Yes TBI-223 - Global Alliance SAD trial launched Yes/Yes AZD5847 Posizolid AstraZenica Completed EBA Yes/No RX-1741 Radezolid Melinta IND for vaginal infections ?/No RBX-7644 Ranbezolid Rabbaxy None found ?/No MRX-4/MRX-1 Contezolid MicuRx Skin infections Yes/No U-100592 Eperezolid ? No clinical trials ?/No PK of Oxazolidinones in Development for TB Steady State PK Parameters Parameter Linezolid 600 Delpazolid 800 mg QD2 mg QD3 Cmax (mg/L) 17.8 8.9 Cmin (mg/L) 2.43 0.1 Tmax (h) 0.87 0.5 T1/2 (h) 3.54 1.7 AUC0-24 (µg*h/mL) 84.5 20.1 1 MIC90 (µg/mL) 0.25 0.5 References 1.
    [Show full text]
  • Proceedings of the Thirtieth Annual Meeting of the American Society for Clinical Investigation Held in Atlantic City, N
    PROCEEDINGS OF THE THIRTIETH ANNUAL MEETING OF THE AMERICAN SOCIETY FOR CLINICAL INVESTIGATION HELD IN ATLANTIC CITY, N. J., MAY 2, 1938 J Clin Invest. 1938;17(4):501-537. https://doi.org/10.1172/JCI100977. Research Article Find the latest version: https://jci.me/100977/pdf PROCEEDINGS OF THE THIRTIETH ANNUAL MEETING OF THE AMERICAN SOCIETY FOR CLINICAL INVESTIGATION HELD IN ATLANTIC CITY, N. J., MAY 2, 1938 READ BEFORE THE SCIENTIFIC SESSION The Successful Treatment of Pernicious Anemia by in powdered form hemostasis was readily obtained in Means of Non-Autolyzed Yeast. By MAXWELL M. hemorrhages following nine dental extractions and three WINTROBE, Baltimore, Md. external wounds in five hemophilic subjects. When ap- It has been the general opinion that yeast, if it pos- plied in liquid form as other hemostatics are usually em- sesses any antianemic potency whatever, is effective only 1 loyed the results were unsatisfactory. Since the co- after autolysis and then only by virtue of its content of agulation time of the circulating blood was unchanged the "extrinsic factor." The observations reported contradict effectiveness of powdered beef globulin substance when this view and indicate that dehydrated yeast which has locally applied to a bleeding wound in hemophilia is not been subjected to autolysis, contains an antiper- attributed to the rapid formation of a firm fibrin clot. nicious anemia substance. Yeast obtained from two dif- The failure of liquid preparations may be due to the ferent sources was effective in the treatment of classical inability to maintain a sufficient concentration of the cases of pernicious anemia.
    [Show full text]
  • Materializing Estrogen and Regulation Under Canada's Food and Drugs Act, 1939-1953 Lara Jessie Tessaro
    Osgoode Hall Law School of York University Osgoode Digital Commons LLM Theses Theses and Dissertations 8-27-2018 Toxic Enactments: Materializing Estrogen and Regulation Under Canada's Food and Drugs Act, 1939-1953 Lara Jessie Tessaro Follow this and additional works at: https://digitalcommons.osgoode.yorku.ca/llm Part of the Legal History Commons TOXIC ENACTMENTS: MATERIALIZING ESTROGEN AND REGULATION UNDER CANADA’S FOOD AND DRUGS ACT, 1939-1953 LARA TESSARO A THESIS SUBMITTED TO THE FACULTY OF GRADUATE STUDIES IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF MASTER OF LAWS GRADUATE PROGRAM IN LAW OSGOODE HALL LAW SCHOOL, YORK UNIVERSITY TORONTO, ONTARIO August 2018 © Lara Tessaro, 2018 ABSTRACT The study describes how estrogen was standardized in Canada, in the 1940s and early 1950s, under the Food and Drugs Act. Contributing to interdisciplinary conversations, it provides an empirical case of how regulatory practices enact material realities. Using archival material, the study describes how estrogen was achieved, in part, through heterogeneous practices of the Canadian Committee on Pharmacopoeial Standards, National Health, and government solicitors. These regulators disagreed on whether, how, and by whom estrogens should be standardized. Rather than resolve these disagreements, Canada enacted multiple regulations purporting to standardize estrogen, and government solicitors practiced “techniques of validating” to render the regulations as lawful. I argue that these regulatory enactments materialized estrogen as a potent, unpredictable, and multiple object. Further, I show how estrogen spawned novel regulatory techniques in Canada, particularly the use of consumer product labels. In this way, estrogen catalyzed an early example of risk regulation in Canada.
    [Show full text]
  • Choline Esters As Absorption-Enhancing Agents for Drug Delivery Through Mucous Membranes of the Nasal, Buccal, Sublingual and Vaginal Cavities
    J|A Europaisches Patentamt 0 214 ® ^KUw ^uroPean Patent O^ice (fl) Publication number: 898 Office europeen des brevets A2 © EUROPEAN PATENT APPLICATION @ Application number: 86401812.2 (3) Int. CI.4: A 61 K 47/00 @ Date of filing: 13.08.86 @ Priority: 16.08.85 US 766377 © Applicant: MERCK & CO. INC. 126, East Lincoln Avenue P.O. Box 2000 @ Date of publication of application : Rahway New Jersey 07065 (US) 18.03.87 Bulletin 87/12 @ Inventor: Alexander, Jose @ Designated Contracting States : 2909 Westdale Court CH DE FR GB IT LI NL Lawrence Kansas 66044 (US) Repta, A.J. Route 6, Box 100N Lawrence Kansas 66046 (US) Fix, Joseph A. 824 Mississippi Lawrence Kansas 66044 (US) @ Representative: Ahner, Francis et al CABINET REGIMBEAU 26, avenue Kleber F-75116 Paris (FR) |j) Choline esters as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal cavities. @ Choline esters are used as drug absorption enhancing agents for drugs which are poorly absorbed from the nasal, oral, and vaginal cavities. ! r ■ i ■ I njndesdruckerei Berlin 0 214 898 Description CHOLINE ESTERS AS ABSORPTION-ENHANCING AGENTS FOR DRUG DELIVERY THROUGH MUCOUS MEMBRANES OF THE NASAL, BUCCAL, SUBLINGUAL AND VAGINAL CAVITIES 5 BACKGROUND OF THE INVENTION The invention relates to a novel method and compositions for enhancing absorption of drugs from the nasal, buccal, sublingual and vaginal cavities by incorporating therein a choline ester absorption enhancing agent. The use of choline esters to promote nasal, buccal, sublingual and vaginal drug delivery offers several advantages over attempts to increase drug absorption from the gastrointestinal tract.
    [Show full text]
  • Fall Cooking Program 2016
    FALL COOKING PROGRAM 2016 auroragov.org/cooking 1891 2016 AURORA, YEARS Welcome Dear Aurora Cooks Community! Hope you are enjoying this fall harvest time of year. We are gearing up for cooler weather and shorter days as we wind down our growing season. Check out all our garden-to-table classes and new series this session! We have The Preserved Pantry, the Frugal Chef and Scratch Baking Basics, as well as many family, kids and teen classes highlighting food from every corner of the world. If you are looking for something to do on a chilly evening, come to a cooking class date night! You can even come with a friend, or as a single. We have some exciting new couples cooking classes, including the Fleetwood Mac Tribute Dinner, complete with music during the class! Come jam out to some tunes and cook with us. See you soon in the kitchen! Katrina and the Aurora Cooks Team TABLE OF CONTENTS Parent/Tot Cooking 2 Parent/Family Cooking 4 Kids Cooking 6 Meadowood Cooking Classes 7 Preteen Cooking 8 Teen Cooking 9 Adult Cooking 15 and Older 11 Adult Cooking 21 and Older 17 Wine Tasting 19 Recipe of the Season 20 All classes will be held at Expo Recreation Center 10955 E. Exposition Ave. unless noted Meadowood Recreation Center • 3045 S. Laredo 1 parent/tot cooking Ages 3-6 with parent. Apple Fest Tiny Italian Pumpkin Treats $38 ($29 Resident) $38 ($29 Resident) $38 ($29 Resident) Celebrate the harvest season with your Create delicious meatballs & veggies your Learn to use pumpkin in lots of different tot! Menu: Apple Zucchini Muffin tot will feel proud they prepared themselves.
    [Show full text]
  • Antibacterial Drugs
    Antibacterial drugs Iwona Smolarek, MD, PhD Department of Clinical Pharmacology The antibacterial drugs destroy or slow down the growth of bacteria They are widely used in medicine and dentistry. They are administered generally and locally, in prophylaxis and treatment. ANTIBIOTICS antimicrobial agents produced by microorganisms synthetic drugs designed based upon the structure of molecules produced in nature by microorganisms CHEMOTHERAPEUTIC AGENTS antimicrobial agents synthesized in the laboratory Colloquially – all antibacterial agents are named antibiotics Antibiotics classification and mechanism of action Antibiotics classification bacteriostatic – slow growth or reproduction of bacteria (macrolides, lincosamides, tetracyclines, sulfonamides and chloramphenicol) bactericidal - kill bacteria (β-lactams, vancomycin, daptomycin, fluoroquinolones, metronidazole, co-trimoxazole) The classification is in part arbitrary because most bacteriostatic drugs are bactericidal at high concentrations, under certain incubation conditions in vitro, and against some bacteria. Β - lactams inhibit bacterial growth by interfering with bacterial cell wall synthesis - bactericidal this group of antibiotic include some groups such as penicillins, cephalosporins, monobactams, carbapenems, and β – lactamase inhibitors Penicillins - classification The penicillin group include: prototype: penicillin G, penicillin V penicillinase – resistant: nafcillin, methilcillin, oxacillin, cloxacillin, dicloxacillin extendend – spectrum: ampicillin, amoxicillin,
    [Show full text]
  • Page-5 Local.Qxd
    DAILY EXCELSIOR, JAMMU MONDAY, MARCH 22, 2021 (PAGE 5) Expired injections case Headless Congress on brink MS, MOs, staff nurses of DH of collapse in J&K: Kavinder Excelsior Correspondent connecting more and more peo- Shopian fined for negligence ple with the party to ensure that Excelsior Correspondent diary," the order reads. JAMMU, Mar 21: Senior the entire J&K becomes a bas- It underlines that no action BJP leader and former Deputy tion of nationalist BJP and there- SRINAGAR, Mar 21: Days on part of the Medical Chief Minister, Kavinder Gupta fore every effort is to be made to after a 6 year-old-girl was Superintendent against the today said that Congress Party spread awareness of schemes given expired injections at negligent staff "speaks about has turned a spent force in J&K launched by PM Modi-led dis- BJP J&K President, Ravinder Raina addressing party leaders Ex-DyCM Tara Chand addressing workers meeting in Khour District Hospital Shopian, the with no significant face left in on Sunday. the negligence of the hospital pensation. He said with full con- meeting at Srinagar on Sunday. -Excelsior/Shakeel District Magistrate Shopian administration." the party to sail it out from the fidence that the next today imposed a fine on the "It is ordered that the offi- troubled waters. Government in J&K will be of Take message of PM to every People feeling cheated due to Medical Superintendent of the cers; Medical Superintendent The senior BJP leader while BJP which shall accelerate the hospital along with 2 doctors and Mohd Yaseen (MO), chairing BJP Working pace of development manifold nook, corner of Valley: Raina and several staff nurses.
    [Show full text]
  • W O 2015/175939 A1 19 November 2015 (19.11.2015) W I PO I P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date W O 2015/175939 A1 19 November 2015 (19.11.2015) W I PO I P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated,for every A61K 9/127 (2006.01) A01N 43/04 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, PCT/US2015/03 1079 DO, DZ, EC, EE, EG, ES, Fl, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, 15 May 2015 (15.05.2015) KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (25) Filing Language: English PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, (26) Publication Language: English SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 61/993,439 15 May 2014 (15.05.2014) US (84) Designated States (unless otherwise indicated,for every 62/042,126 26 August 2014 (26.08.2014) US kind of regional protection available): ARIPO (BW, GH, 62/048,068 9 September 2014 (09.09.2014) US GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, 62/056,296 26 September 2014 (26.09.2014) US TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, (71) Applicant: INSMED INCORPORATED [US/US]; 10 DK, EE, ES, Fl, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, Finderne Avenue, Building N'10, Bridgewater, NJ 08807- LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, 3365 (US).
    [Show full text]
  • EMA/CVMP/158366/2019 Committee for Medicinal Products for Veterinary Use
    Ref. Ares(2019)6843167 - 05/11/2019 31 October 2019 EMA/CVMP/158366/2019 Committee for Medicinal Products for Veterinary Use Advice on implementing measures under Article 37(4) of Regulation (EU) 2019/6 on veterinary medicinal products – Criteria for the designation of antimicrobials to be reserved for treatment of certain infections in humans Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged. Introduction On 6 February 2019, the European Commission sent a request to the European Medicines Agency (EMA) for a report on the criteria for the designation of antimicrobials to be reserved for the treatment of certain infections in humans in order to preserve the efficacy of those antimicrobials. The Agency was requested to provide a report by 31 October 2019 containing recommendations to the Commission as to which criteria should be used to determine those antimicrobials to be reserved for treatment of certain infections in humans (this is also referred to as ‘criteria for designating antimicrobials for human use’, ‘restricting antimicrobials to human use’, or ‘reserved for human use only’). The Committee for Medicinal Products for Veterinary Use (CVMP) formed an expert group to prepare the scientific report. The group was composed of seven experts selected from the European network of experts, on the basis of recommendations from the national competent authorities, one expert nominated from European Food Safety Authority (EFSA), one expert nominated by European Centre for Disease Prevention and Control (ECDC), one expert with expertise on human infectious diseases, and two Agency staff members with expertise on development of antimicrobial resistance .
    [Show full text]
  • 206 Antibacterials
    206 Antibacterials Arbekacin Sulfate (rINNM) Profile Avilamycin is an antibacterial that has been used in veterinary ABK (arbekacin); AHB-DBK (arbekacin); Arbekacin Sulphate; Ar- HO medicine as a growth promotor. békacine, Sulfate d’; Arbekacini Sulfas; HABA-Dibekacin (ar- O bekacin); Sulfato de arbekacina. O-3-Amino-3-deoxy-α-D-glu- HH copyranosyl-(1→4)-O-[2,6-diamino-2,3,4,6-tetradeoxy-α-D- S N CH3 erythro-hexopyranosyl-(1→6)]-N′-[(2S)-4-amino-2-hydroxybu- H Avoparcin (BAN, USAN, rINN) tyryl]-2-deoxy-L-streptamine sulphate. O NH N CH3 Avoparcina; Avoparcine; Avoparcinum; Compound 254. O Арбекацина Сульфат O Авопарцин COOH C22H44N6O10,xH2S04. H3C CAS — 37332-99-3. CAS — 51025-85-5 (arbekacin). N NH2 H Profile Avoparcin is a glycopeptide antibiotic usually produced by Amy- Pharmacopoeias. Jpn includes the trihydrate. colatopsis coloradensis (Streptomyces candidus). It has been in- OH corporated into animal feedstuffs to promote growth. Profile NH2 OH ◊ There is evidence of cross-resistance between avoparcin and Aspoxicillin is a ureidopenicillin that has been given intrave- 1 nously in the treatment of susceptible infections. vancomycin. Suggestions that vancomycin-resistant organisms could enter the human population from the food chain as a result O OH O NH2 of the use of avoparcin as a growth promotor in animals2,3 were O disputed by the manufacturers of avoparcin.4,5 After a ban in the EU on the use of avoparcin as a growth promotor in animals H N H N O OH Astromicin Sulfate (USAN, pINNM) 2 2 there has been some evidence6 of a decrease in the occurrence of H2N Abbott-44747; Astromicin Sulphate; Astromicine, Sulfate d’; As- vancomycin-resistant enterococci in poultry meat.
    [Show full text]
  • Anew Drug Design Strategy in the Liht of Molecular Hybridization Concept
    www.ijcrt.org © 2020 IJCRT | Volume 8, Issue 12 December 2020 | ISSN: 2320-2882 “Drug Design strategy and chemical process maximization in the light of Molecular Hybridization Concept.” Subhasis Basu, Ph D Registration No: VB 1198 of 2018-2019. Department Of Chemistry, Visva-Bharati University A Draft Thesis is submitted for the partial fulfilment of PhD in Chemistry Thesis/Degree proceeding. DECLARATION I Certify that a. The Work contained in this thesis is original and has been done by me under the guidance of my supervisor. b. The work has not been submitted to any other Institute for any degree or diploma. c. I have followed the guidelines provided by the Institute in preparing the thesis. d. I have conformed to the norms and guidelines given in the Ethical Code of Conduct of the Institute. e. Whenever I have used materials (data, theoretical analysis, figures and text) from other sources, I have given due credit to them by citing them in the text of the thesis and giving their details in the references. Further, I have taken permission from the copyright owners of the sources, whenever necessary. IJCRT2012039 International Journal of Creative Research Thoughts (IJCRT) www.ijcrt.org 284 www.ijcrt.org © 2020 IJCRT | Volume 8, Issue 12 December 2020 | ISSN: 2320-2882 f. Whenever I have quoted written materials from other sources I have put them under quotation marks and given due credit to the sources by citing them and giving required details in the references. (Subhasis Basu) ACKNOWLEDGEMENT This preface is to extend an appreciation to all those individuals who with their generous co- operation guided us in every aspect to make this design and drawing successful.
    [Show full text]